Avammune Secures $12M to Advance Cancer Therapies

• Avammune Therapeutics has successfully raised $12 million in a Series A funding round.
• Capital 2B, Shastra VC, and Kotak Alternate Asset Managers led the investment.
• The funds will enhance Avammune's IP portfolio and develop the lead candidate AVA-NP-695.
• Founded in 2020, Avammune focuses on small molecule medicines targeting the immune system.
• The pharmaceutical landscape in India continues to evolve with innovative startups like Avammune.

Source: TechCrunch